Peptide Therapeutics Market by Technology, Drug Class, Route of Administration, Application, End User, Manufacturing Type

List of Tables

The Peptide Therapeutics Market was valued at USD 33.06 billion in 2023, expected to reach USD 35.76 billion in 2024, and is projected to grow at a CAGR of 8.35%, to USD 57.97 billion by 2030.

Peptide therapeutics, a vital segment within the biotechnology and pharmaceutical sectors, focus on the use of peptides as drugs due to their high specificity, safety, and efficacy. These naturally occurring biological molecules, consisting of short chains of amino acids, cater primarily to areas such as oncology, metabolic disorders, and infectious diseases. The necessity for peptide therapeutics arises from their ability to precisely target disease pathways with fewer side effects compared to traditional small molecule drugs. They find application in drug delivery systems, cancer immunotherapy, and as antimicrobial agents. Key end-users include hospitals, specialized clinics, research institutes, and pharmaceutical companies. Market growth is driven by expanding research into biologically active peptides, escalating prevalence of chronic diseases, and advancements in peptide synthesis and drug delivery technologies. Opportunities are ripe, especially in personalized medicine and regenerative therapies, enhanced by innovations in peptide engineering and nanotechnology. Collaboration between academic research centers and pharmaceutical companies can further uncover novel applications. However, market expansion faces challenges such as high production costs, complexities in peptide stability and delivery, and stringent regulatory hurdles that can impede R&D processes. Additionally, the competitive landscape is intensified by the constant influx of biotechnological advancements, necessitating agile research strategies. Opportunities exist in areas like peptide-based vaccines and diagnostics where demand is burgeoning. Advances in chemical synthesis, such as the development of solid-phase peptide synthesis, present pathways for overcoming current production and cost limitations. Firms should focus on multisector partnerships to leverage comprehensive expertise and resource sharing. The market's dynamic nature underscores the potential for groundbreaking treatments, with ongoing research directed at expanding therapeutic peptides' stability and delivery mechanisms likely to usher in new growth avenues. Exploring these areas for innovation promises to reshape therapeutic approaches in significant ways.

KEY MARKET STATISTICS
Base Year [2023]	USD 33.06 billion
Estimated Year [2024]	USD 35.76 billion
Forecast Year [2030]	USD 57.97 billion
CAGR (%)	8.35%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Peptide Therapeutics Market

The Peptide Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Prevalence of chronic diseases and need for effective therapeutic options
- Exponential use of peptides in aesthetic dermatology
Market Restraints
- Adverse recalls of peptide therapeutics
Market Opportunities
- Ongoing R&D activities for new peptide development worldwide
- Shift toward personalized medicine and identification of peptide biomarkers
Market Challenges
- Production complexity and bioavailability issues of peptide therapeutics

Porter's Five Forces: A Strategic Tool for Navigating the Peptide Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Peptide Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Peptide Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Peptide Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Peptide Therapeutics Market

A detailed market share analysis in the Peptide Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Peptide Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Peptide Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Peptide Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AmbioPharm, Inc., Amgen Inc., Amide Technologies, Inc., AstraZeneca PLC, Bachem Holding AG, Biosynth Ltd., Bristol Myers Squibb Company, Cidara Therapeutics, Inc., Corden Pharma International GmbH, Cybrexa, Inc., Eccogene, Eli Lilly and Company, Exelixis, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Ipsen Group, IRBM S.p.A., Ironwood Pharmaceuticals, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Otsuka Pharmaceutical Co., Ltd., Peptidream Co., Ltd., Perpetual Medicines Corporation, Pfizer Inc., Piramal Pharma Limited, PolyPeptide Group AG, RELIEF THERAPEUTICS Holding SA, Sanofi S.A., Sanyou Biopharmaceuticals Co., Ltd., Shanghai Full-Life Technologies Co, Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, WuXi AppTec Co., Ltd., and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Peptide Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Technology, market is studied across Hybrid Phase, Liquid Phase, and Solid Phase.
Based on Drug Class, market is studied across Adrenocorticotropic Hormone, Calcitonin, Insulin, Leuprorelin, Octreotide, and Vasopressin.
Based on Route of Administration, market is studied across Intravenous Administration, Nasal & Pulmonary Administration, Oral Administration, and Transdermal Administration.
Based on Application, market is studied across Cardiovascular Disorders, Gastrointestinal Disorders, Infectious Disorders, Neurological Disorders, and Oncology.
Based on End User, market is studied across Hospitals & Clinics, Long-term Care Facilities, and Research Laboratories.
Based on Manufacturing Type, market is studied across Contract Manufacturing Organization and In-house.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, Indiana, Maryland, Massachusetts, Minnesota, New Jersey, New York, North Carolina, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-030EE4851583

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Prevalence of chronic diseases and need for effective therapeutic options
  - 5.1.1.2. Exponential use of peptides in aesthetic dermatology
- 5.1.2. Restraints
  - 5.1.2.1. Adverse recalls of peptide therapeutics
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing R&D activities for new peptide development worldwide
  - 5.1.3.2. Shift toward personalized medicine and identification of peptide biomarkers
- 5.1.4. Challenges
  - 5.1.4.1. Production complexity and bioavailability issues of peptide therapeutics
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Rising utilization of solid phase approach for synthesis of complex peptides
- 5.2.2. Drug Class: Increasing need for insulin to regulate glucose metabolism for type 1 and type 2 diabetes
- 5.2.3. Route of Administration: Rising adoption of intravenous administration due to peptide therapeutics immediacy and effectiveness in acute hospital care settings
- 5.2.4. Application: Widening use of peptide therapeutics in cardiovascular disorders to simulate the action of endogenous peptides involved in blood pressure regulation
- 5.2.5. End User: Expanding the use of peptide therapeutics in hospitals and clinics to address and manage patient conditions
- 5.2.6. Manufacturing Type: Increasing adoption of CMOs owing to the need for specialized manufacturing capabilities and the ability to scale production rapidly
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Peptide Therapeutics Market, by Technology

6.1. Introduction
6.2. Hybrid Phase
6.3. Liquid Phase
6.4. Solid Phase

7. Peptide Therapeutics Market, by Drug Class

7.1. Introduction
7.2. Adrenocorticotropic Hormone
7.3. Calcitonin
7.4. Insulin
7.5. Leuprorelin
7.6. Octreotide
7.7. Vasopressin

8. Peptide Therapeutics Market, by Route of Administration

8.1. Introduction
8.2. Intravenous Administration
8.3. Nasal & Pulmonary Administration
8.4. Oral Administration
8.5. Transdermal Administration

9. Peptide Therapeutics Market, by Application

9.1. Introduction
9.2. Cardiovascular Disorders
9.3. Gastrointestinal Disorders
9.4. Infectious Disorders
9.5. Neurological Disorders
9.6. Oncology

10. Peptide Therapeutics Market, by End User

10.1. Introduction
10.2. Hospitals & Clinics
10.3. Long-term Care Facilities
10.4. Research Laboratories

11. Peptide Therapeutics Market, by Manufacturing Type

11.1. Introduction
11.2. Contract Manufacturing Organization
11.3. In-house

12. Americas Peptide Therapeutics Market

12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States

13. Asia-Pacific Peptide Therapeutics Market

13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam

14. Europe, Middle East & Africa Peptide Therapeutics Market

14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom

15. Competitive Landscape

15.1. Market Share Analysis, 2023
15.2. FPNV Positioning Matrix, 2023
15.3. Competitive Scenario Analysis
- 15.3.1. Novartis and PeptiDream collaborated to develop advanced oncology therapies with a USD 180 million deal a USD 2.8 billion deal
- 15.3.2. Expansion of GMP Capacities at CordenPharma Frankfurt: Elevating Early-Phase Peptide API Manufacturing
- 15.3.3. Revolutionizing Peptide Therapeutics: Orbis Medicines Innovates for Oral Drug Delivery
- 15.3.4. Copenhagen's Orbis Medicines launched peptide therapeutics with advanced macrocyclic technology for enhanced oral bioavailability
- 15.3.5. Expanding Facilities in Peptide Therapeutic Production: WuXi AppTec's Strategic Growth
- 15.3.6. Glenmark Pharmaceuticals Announces Biosimilar Liraglutide Launch in India to Revolutionize Anti-Diabetic Treatment
- 15.3.7. Amide Technologies' Novel Manufacturing Platform and Strategic Capital Advancement
- 15.3.8. Strategic Acquisition Elevates Pharmathen's Position in the Peptide Therapeutics Market
- 15.3.9. Biosynth Solidifies Market Position with Strategic Acquisition of Pepceuticals
- 15.3.10. Strategic Collaboration between PeptiDream and Genentech to Advance Peptide-Radioisotope Therapeutics
- 15.3.11. Merck and IRBM Forge Forward in Peptide Therapeutics: A Partnership to Expand and Innovate in Biopharmaceuticals
- 15.3.12. Fujitsu Launches Pioneering Bio-Drug Design Accelerator Focused on Advancing Peptide Therapeutics in Cancer and CNS Regeneration
- 15.3.13. Comprehensive Support for Peptide Therapeutics Development from Conception to Manufacturing for Introducing SynCrest's CRDMO Service

Companies Mentioned

1. AbbVie Inc.
2. AmbioPharm, Inc.
3. Amgen Inc.
4. Amide Technologies, Inc.
5. AstraZeneca PLC
6. Bachem Holding AG
7. Biosynth Ltd.
8. Bristol Myers Squibb Company
9. Cidara Therapeutics, Inc.
10. Corden Pharma International GmbH
11. Cybrexa, Inc.
12. Eccogene
13. Eli Lilly and Company
14. Exelixis, Inc.
15. F. Hoffmann-La Roche Ltd.
16. GlaxoSmithKline PLC
17. Ipsen Group
18. IRBM S.p.A.
19. Ironwood Pharmaceuticals, Inc.
20. Merck KGaA
21. Novartis AG
22. Novo Nordisk A/S
23. Otsuka Pharmaceutical Co., Ltd.
24. Peptidream Co., Ltd.
25. Perpetual Medicines Corporation
26. Pfizer Inc.
27. Piramal Pharma Limited
28. PolyPeptide Group AG
29. RELIEF THERAPEUTICS Holding SA
30. Sanofi S.A.
31. Sanyou Biopharmaceuticals Co., Ltd.
32. Shanghai Full-Life Technologies Co, Ltd.
33. Takeda Pharmaceutical Company Limited
34. Teva Pharmaceutical Industries Limited
35. WuXi AppTec Co., Ltd.
36. Zealand Pharma A/S